Browse by Audience
Skip to content
Papers of the Week
Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.
Abstract
Migraine is associated with activation of the trigeminovascular system, release of calcitonin gene-related peptide (CGRP) and dilation of dural arteries. Novel treatments target calcitonin gene-related peptide or its receptor, which are present in all vascular beds, raising cardiovascular concerns. Erenumab is a human CGRP-receptor antibody approved for the prophylactic treatment of migraine.